Answers are grounded in this paper and cite their sources.
Immunophenotyping identifies CD8+CD38+ T cells as markers of early relapse in multiple myeloma, indicating a high-risk group.
• PD1 + bone marrow T cells portend early relapse independent of cytogenetic risk, maintenance therapy, or treatment response. • Circulating CD38-expressing CD8 T cells segregate early relapse from prolonged remission with >80% AUC in a risk stratification model. Multiple myeloma (MM) patients who experience early relapse (ER) within 24 months of autologous stem cell transplantation (ASCT) have inferior overall survival and represent a functionally high-risk (HR) subgroup. To investigate immune features of functionally HR MM, we performed immunohistochemistry (IHC) of the bone marrow and high-dimensional flow cytometry-based phenotyping of peripheral blood to evaluate the T-cell compartment of MM patients at day 100 post-ASCT. An initial IHC-based analysis of a MM patient cohort (n=110) with long-term follow-up implicated CD3 + PD-1 + T cells as a marker of functionally HR disease independent of maintenance therapy or cytogenetics, suggesting a role for activated T cells as a biomarker of disease biology. Next, to further refine the immunophenotype associated with ER, we conducted a flow cytometry-based analysis of peripheral blood samples from BMT CTN 0702 trial participants (NCT01109004) with ER (n=45) or long-term remission (LR, n=51), defined as not relapsed beyond 4 years of follow-up. Unsupervised clustering followed by multivariate logistic regression identified the differential expression of HLA-DR, granzyme B, CTLA4, CD27, TIGIT, and CD38 within discrete T-cell subsets, distinguishing ER from LR patients. After variable reduction and validation, CD38 expression by CD8 + Eomes + effector memory T cells emerged as the most predictive feature segregating ER from LR patients, with an area under the curve (AUC) of 86%. This immunophenotype was corroborated in a separate standard-of-care cohort (n=18). Thus, flow cytometric analysis of peripheral blood at day 100 post-ASCT identified a CD8 + CD38 + T-cell subpopulation as a key feature of immunologically high-risk (HR-I) MM.
No takes yet. Share an insight, caveat, or question.
Mehanna et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: